Slingshot Biosciences’ Post

The latest blog highlights show you how Levitation Technology™ is revolutionizing sample preparation, ensuring higher cell viability and boosting the accuracy and reliability of assays. Read the blog from LevitasBio to learn more! #Blog #Revolution #Cells #Explore #CellTherapy #Research

BLOG ALERT: Cell-based assays sit at the core of cell therapy research and development and are crucial for ensuring the safety and efficacy of new treatments. However, the success of these assays heavily relies on the viability of cell samples, which can be compromised by conventional separation techniques. Our latest blog highlights how Levitation Technology™ is revolutionizing sample preparation, ensuring higher cell viability and boosting the accuracy and reliability of assays. Discover how levitation innovation is transforming cell therapy R&D for safer, more effective treatments. Dive into the full story here: https://bit.ly/3UFbETL #CellTherapyResearch #LevitationTechnology #SamplePreparation

Learn how to harness the power of the CFU assay as a potency assay in hematopoietic cell therapy with insights from Dr. Colin Hammond of STEMCELL Technologies. Register for this upcoming webinar, here: https://bit.ly/3WZK2u2 Key topics include: ☑️ The CFU assay and its characteristics as a biological tool in assessing hematopoietic stem and progenitor cells ☑️ Utility of using bioassays to assess product potency in hematopoietic cell therapy workflows ☑️ Methods to validate the CFU assay as an in-house potency assay ☑️ Ways to standardize and improve CFU assay throughput #CellTherapy #Assay

Are you developing allogeneic cell therapies? How do you guarantee their compliant aseptic manufacturing?   To get the answers to those questions, you should attend Michela Castellani-Kleinschroth and Koji Ushioda's speech tomorrow at #ATE24     Phacilitate SKAN #AT #AdvancedTherapiesEurope #CellTherapy #AllogeneicTherapy

🚀 Elevate your cell therapy research with Alerion™— learn more at ASGCT 2024! Akadeum Life Sciences is excited to showcase our Alerion™ Microbubble Cell Separation System, a breakthrough in cell separation technology that’s setting new standards for efficiency and cell viability. Why choose Alerion™? 📈 Efficient: Secure larger quantities of healthier cells for your critical projects. ⚡Scalable: Process a wide range of cells to meet cell therapy dosing requirements. ⏱ Fast: Streamline your workflow from setup to separation in under an hour, even when handling multiple samples. But don't just read about it—experience the difference that Alerion™ can make in your lab. Visit us at Booth #2244 at ASGCT 2024 from May 7-11 to see Alerion™ in action and discuss how we can help transform your cell therapy workflows with unparalleled efficiency and outcomes. 🤝 Let's connect, innovate, and advance the future of cell therapy together. Contact our team today to find out more!

Now that I’ve spent two months getting up to speed on all things Nomic Bio and #nELISA they are finally letting me out in public to speak with customers 😂 In all seriousness, this onboarding has been truly inspiring and solidified my initial hunch that this was a one-of-a-kind place with a legitimate paradigm-shifting technology. The opportunity to introduce researchers to our novel #proteomics solution at events like the #IOSummit here in Philadelphia is extremely motivating. In this industry, it isn’t often that you’re in a postition to solve several long-standing technical challenges while also lowering cost and increasing throughput! And while this is just the beginning, it’s becoming increasingly clear that access to a high-plex, #quantitative #immunoassay panel that enables turnkey flexibility while significantly reducing end-to-end cost is already redefining how, and more importantly how often, proteomics is applied from #drugdiscovery screening campaigns to translational #biomarker studies. I’m looking forward to sharing our advancements with a growing audience of scientists over the coming months and can’t wait to see how we together accelerate and ultimately enable the promise of proteomics.

📝App Note Alert! Discover how highly potent TNF-α-secreting T cells from blood samples can be identified in just 7 hours using our Xdrop double-emulsion droplet-based workflow. 🔬 Summary: ·        Single-cell assays reveal highly potent cells within the population often missed in bulk assays. ·        Xdrop workflow reveals highly potent T cells, critical for cell therapy research. ·        No overnight incubation required, providing accurate results within a single working day. 📚 Read the full app note on our website and discover how Xdrop technology is transforming single-cell analysis! https://lnkd.in/d56CfKP3 #Biotechnology #CellTherapy #SingleCellAnalysis #singlecells #Cytokines #XdropTechnology #FlowCytometry #Innovation #Droplet #Microfluidics

Gene&Cell Therapy >> Avenge Bio, a cell therapy biotech from Rice, is closed: Cell therapy startup Avenge Bio has shut down, Endpoints News has learned. Chris Garabedian The company ceased all operations and sold its lead asset, Xontogeny CEO Chris Garabedian told Endpoints in an email. Xontogeny co-led Avenge Bio’s $45 million Series A in 2022. Avenge’s website was also updated last month to say the company had “permanently closed.” The program, called AVB-001, was returned to Rice University, from where Avenge Bio was launched, a spokesperson who represents newco efforts told Endpoints. AVB-001 is expected to be “part of a new company that is launched this month or in September,” the spokesperson added in an email. Avenge Bio was researching how best to develop cell therapies for solid tumors. AVB-001 was designed to produce IL-2 in order to treat peritoneal cancers such as ovarian cancer. A Phase 1/2 trial had gotten underway in January 2023. #lucidquest #genetherapy #celltherapy

5 billion T cells from 1L of media? This is possible. See how the Wilson Wolf Manufacturing, LLC G-Rex bioreactor achieved exceptional output in cell therapy production. Download the case study to learn more: https://lnkd.in/efQDr2Eb #celltherapy #efficiency #G-Rex

#iPSCs, with their promise and complexity, are shaping the future of advanced cell therapies. They present unique challenges and opportunities in gene-editing, including the integration of CRISPR technology for iPSC-derived allogeneic cell therapies. Gain valuable insights into the challenges of employing gene-editing techniques for iPSC-derived therapies from Suzanne Snellenberg, Cellistic's VP of Cell Line Development. Read the full article at the link below and feel to reach out for more information! 💡🔗 https://hubs.ly/Q02xctr80 #iPSCs #GeneEditing #article